Silexion Therapeutics (SLXN) Competitors

ESGEN Acquisition (NASDAQ:ESAC) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap unclassified companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.

Which has more risk and volatility, ESAC or SLXN?

ESGEN Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500.

Does the MarketBeat Community prefer ESAC or SLXN?

ESGEN Acquisition and Silexion Therapeutics both received 0 outperform votes by MarketBeat users.

Company	Underperform	Outperform
ESGEN Acquisition	N/A	N/A
Silexion Therapeutics	N/A	N/A

Which has higher valuation and earnings, ESAC or SLXN?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ESGEN Acquisition	N/A	N/A	N/A	N/A	N/A
Silexion Therapeutics	N/A	N/A	$260K	N/A	N/A

Do analysts rate ESAC or SLXN?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ESGEN Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Silexion Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is ESAC or SLXN more profitable?

ESGEN Acquisition's return on equity of 0.00% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ESGEN Acquisition	N/A	N/A	N/A
Silexion Therapeutics	N/A	-11.33%	-32.34%

Does the media favor ESAC or SLXN?

In the previous week, Silexion Therapeutics had 1 more articles in the media than ESGEN Acquisition. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for ESGEN Acquisition. Silexion Therapeutics' average media sentiment score of 1.89 beat ESGEN Acquisition's score of 0.00 indicating that Silexion Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ESGEN Acquisition	Neutral
Silexion Therapeutics	Very Positive

Do insiders and institutionals have more ownership in ESAC or SLXN?

26.2% of ESGEN Acquisition shares are held by institutional investors. 4.2% of ESGEN Acquisition shares are held by company insiders. Comparatively, 4.9% of Silexion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ESGEN Acquisition beats Silexion Therapeutics on 4 of the 7 factors compared between the two stocks.